Nexalin Technology Inc. (NXL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Nexalin Technology Inc. stock (NXL) is currently trading at $0.40. Nexalin Technology Inc. PS ratio (Price-to-Sales) is 48.27. Analyst consensus price target for NXL is $4.00. WallStSmart rates NXL as Sell.
- NXL PE ratio analysis and historical PE chart
- NXL PS ratio (Price-to-Sales) history and trend
- NXL intrinsic value — DCF, Graham Number, EPV models
- NXL stock price prediction 2025 2026 2027 2028 2029 2030
- NXL fair value vs current price
- NXL insider transactions and insider buying
- Is NXL undervalued or overvalued?
- Nexalin Technology Inc. financial analysis — revenue, earnings, cash flow
- NXL Piotroski F-Score and Altman Z-Score
- NXL analyst price target and Smart Rating
Nexalin Technology Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Nexalin Technology Inc. (NXL) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Nexalin Technology Inc. (NXL) Key Strengths (1)
Trading at 1.60x book value, attractively priced
Supporting Valuation Data
Nexalin Technology Inc. (NXL) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -49.60%, a shrinking business
Very expensive at 48.3x annual revenue
Very low institutional interest at 6.61%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Nexalin Technology Inc. (NXL) Detailed Analysis Report
Overall Assessment
This company scores 16/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 8.0/10) while 6 fall into concern territory (avg 1.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (1.60) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (48.27) suggest expensive pricing. Growth concerns include Revenue Growth at -49.60%, which may limit upside. Profitability pressure is visible in Return on Equity at -178.50%, Operating Margin at -12924.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -178.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -49.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NXL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NXL's Price-to-Sales ratio of 48.27x sits near its historical average of 51.07x (14th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 14% below its historical high of 55.86x set in Mar 2026, and 3% above its historical low of 46.97x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~55.9x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Nexalin Technology Inc. (NXL) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Nexalin Technology Inc. operates as a stable business with moderate growth and solid fundamentals. Revenue reached 156,930 with 50% decline year-over-year.
Key Findings
Spending 144% of revenue (226,520) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 50% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -1M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 4.10, so expect amplified moves relative to the broader market.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Nexalin Technology Inc..
Bottom Line
Nexalin Technology Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Nexalin Technology Inc.(NXL)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Nexalin Technology Inc. is a pioneering player in the medical technology sector, specializing in advanced therapies for neurological and psychiatric disorders. The company develops proprietary transcranial electrical stimulation devices that offer non-invasive treatment options for conditions such as anxiety, depression, and substance addiction. With a strong emphasis on cutting-edge research and mental health improvement, Nexalin is positioned to capitalize on the growing demand for innovative healthcare solutions. Its strategic focus on enhancing patient outcomes through technological advancements highlights its potential for substantial growth in the rapidly evolving digital health landscape.